Also, pembrolizumab monotherapy improved the OS as first-line monotherapy in locally advanced or metastatic NSCLC patients expressing PD-L1 at least 1% from tumor cells (Paz-Ares et al., 2019). Here, CD274 is linked to neoplasm.